These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18566849)

  • 1. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis.
    Romero-Sánchez C; Robinson WH; Tomooka BH; Londoño J; Valle-Oñate R; Huang F; Deng X; Zhang L; Yang C; Yu DT
    Clin Rheumatol; 2008 Nov; 27(11):1429-35. PubMed ID: 18566849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis.
    Stone MA; Payne U; Pacheco-Tena C; Inman RD
    Ann Rheum Dis; 2004 Jan; 63(1):84-7. PubMed ID: 14672897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
    Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
    Wendling D; Cedoz JP; Racadot E
    Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis.
    Haroon N; Tsui FW; O'Shea FD; Chiu B; Tsui HW; Zhang H; Marshall KW; Inman RD
    Ann Rheum Dis; 2010 Jan; 69(1):297-300. PubMed ID: 19103635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
    Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.
    Miranda-Filloy JA; López-Mejias R; Genre F; Carnero-López B; Ochoa R; Diaz de Terán T; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
    Clin Exp Rheumatol; 2013; 31(3):365-71. PubMed ID: 23294554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
    Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
    Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab.
    Pieringer H; Stuby U; Pohanka E; Biesenbach G
    Clin Rheumatol; 2010 Jul; 29(7):723-7. PubMed ID: 20162315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppressors of cytokine signalling in ankylosing spondylitis and their associations with disease severity, acute-phase reactants and serum cytokines.
    Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
    Clin Exp Rheumatol; 2016; 34(1):100-5. PubMed ID: 26812031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.
    Visvanathan S; Wagner C; Marini JC; Baker D; Gathany T; Han J; van der Heijde D; Braun J
    Ann Rheum Dis; 2008 Apr; 67(4):511-7. PubMed ID: 17644552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in two patients with juvenile ankylosing spondylitis.
    Schmeling H; Horneff G
    Rheumatol Int; 2004 May; 24(3):173-6. PubMed ID: 14648110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.